期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 9, 页码 2159-2174出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1413186
关键词
Lymphoma and Hodgkin disease; lymphocytes; cell cycle and apoptosis changes; drug resistance; molecular genetics
资金
- Canadian Institute for Health Research (CIHR) [300738, 299607]
- Terry Fox Foundation (Canada) [2390b02f443001b62e3-fe0408dccc681, 1043]
- Cole Foundation
- CIHR
- Roche Canada
- Roche
- Abbvie
- Lundbeck
- Seattle Genetics
- Janssen
- Gilead
Relapse occurs in 10-40% of Burkitt lymphoma (BL) patients that have completed intensive chemotherapy regimens and is typically fatal. While treatment-naive BL has been characterized, the genomic landscape of BL at the time of relapse (rBL) has never been reported. Here, we present a genomic characterization of two rBL patients. The diagnostic samples had mutations common in BL, including MYC and CCND3. Additional mutations were detected at relapse, affecting important pathways such as NFB (IKBKB) and MEK/ERK (NRAS) signaling, glutamine metabolism (SIRT4), and RNA processing (ZFP36L2). Genes implicated in drug resistance were also mutated at relapse (TP53, BAX, ALDH3A1, APAF1, FANCI). This concurrent genomic profiling of samples obtained at diagnosis and relapse has revealed mutations not previously reported in this disease. The patient-derived cell lines will be made available and, along with their detailed genetics, will be a valuable resource to examine the role of specific mutations in therapeutic resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据